Streetbeat News

Analyst Ratings

NARI

Stifel analyst Mathew Blackman has initiated coverage on Inari Medical (NASDAQ:NARI) with a Hold rating and set a price target of $50.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 8:46 pm

EDIT

Jones Trading has initiated coverage on Editas Medicine with a Buy rating and set a price target of $13.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 8:43 pm

DCOM

Dime Community Bancshares (NASDAQ:DCOM) has been analyzed by four analysts, showing a range of opinions from bullish to bearish. Recent analyst actions include raised ratings and price targets, with an average 12-month price target of $28.62, up from $25.75. Despite positive analyst sentiment, Dime Community Bancshares faces financial challenges, including declining revenue growth, low net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 8:01 pm

AMAT

Financial giants have shown a bearish sentiment towards Applied Materials (NASDAQ:AMAT) with 65% of unusual options trades being bearish. Despite this, the stock is currently trading slightly up at $187.65. Analysts have mixed ratings with a consensus target price of $204.0.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 8:00 pm

PM

The options market shows a bullish sentiment towards Philip Morris Intl (NYSE:PM), with 14 call trades totaling $682,665 and 2 put trades totaling $66,002. Analysts have mixed ratings, with price targets ranging from $105 to $145. The stock is currently down 2.3% at $123.07.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 8:00 pm

RIVN

Rivian Automotive (NASDAQ:RIVN) has seen unusual options activity, with a significant amount of bearish sentiment from large investors. The options trades indicate a price range expectation of $5.0 to $22.5. Analysts have mixed ratings, with recent downgrades and a target price of $18.0.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 8:00 pm

TDOC

Teladoc Health (NYSE:TDOC) has received mixed analyst ratings, with a recent downward trend in price targets. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Teladoc faces financial challenges, including declining revenue, negative net margin, and high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 8:00 pm

DADA

Dada Nexus reported its earnings and received an upgrade from Citigroup on August 21. This correction clarifies the date of these events.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 7:23 pm

PODD

Insulet (NASDAQ:PODD) has been analyzed by five analysts, showing a range of opinions from bullish to bearish. Recent analyst actions include raising and lowering price targets, with an average 12-month target of $242.4, up 5.85% from the previous $229. Insulet's financial performance is strong, with high revenue growth, net margin, ROE, and ROA, but it faces challenges with a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

September 17, 2024 | 7:00 pm

EWTX

RBC Capital analyst Leonid Timashev has reiterated an 'Outperform' rating for Edgewise Therapeutics (NASDAQ:EWTX) and maintained a price target of $32.

Portfolio Pulse from Benzinga Newsdesk

September 17, 2024 | 6:57 pm